Pericytes, mesenchymal stem cells and their contributions to tissue repair

Wong, Suet‐Ping; Rowley, Jessica E.; Redpath, Andia N.; Tilman, Jessica; Fellous, Tariq G.; Johnson, Jill

doi:10.1016/j.pharmthera.2015.03.006

Cited by 143 publications

(117 citation statements)

References 153 publications

(229 reference statements)

Supporting

Mentioning

110

Contrasting

Unclassified

Order By: Relevance

“…[36][37][38] CXCL12 is produced locally in damaged tissues and is reported to be critical for the mobilization and recruitment of BM stem/progenitor cells to the site of injury. [39][40][41][42][43][44][45] Taken together, these studies indicate that the relative level of CXCL12 in the blood and BM is one factor that regulates progenitor cell retention/mobilization under homeostasis and in disease. Understanding this mechanism of retention has led to the development of CXCR4 antagonists as HPC-mobilizing drugs.…”

Section: Discussionmentioning

confidence: 79%

“…[48][49][50] In addition, MPC mobilization may enhance tissue repair in the context of tissue injury, such as cardiovascular disease or a musculoskeletal injury. 45,49,[51][52][53] Acknowledgments KRH3955 was kindly donated by Kureha Corporation (Pharmaceuticals and Agrochemicals Division, Tokyo, Japan). Chalcone 4-phosphate was kindly donated by Dominique Bonnet (LabEx Medalis, Faculté de Pharmacie, Laboratoire d'Innovation Thérapeutique, Centre National de la Recherche Scientifique/Université de Strasbourg, Illkirch, France).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Two distinct CXCR4 antagonists mobilize progenitor cells in mice by different mechanisms

et al. 2017

Self Cite

View full text Add to dashboard Cite

Pharmacological mobilization of hematopoietic progenitor cells (HPCs) is used clinically to harvest HPCs for bone marrow transplants. It is now widely accepted that the CXCR4:CXCL12 chemokine axis plays a critical role in the retention of HPCs in the bone marrow, and CXCR4 antagonists have been developed for their mobilization. The first of this class of drugs to be US Food and Drug Administration-approved was the bicyclam AMD3100. In addition to mobilizing HPCs and leukocytes in naïve mice, AMD3100 has been shown to mobilize mesenchymal progenitor cells (MPCs) in vascular endothelial growth factor (VEGF-A) pretreated mice. AMD3100 binds to the transmembrane region of CXCR4 and is thought to mobilize HPCs by reversing the gradient of CXCL12 across the bone marrow endothelium. Consistent with this hypothesis, our data show that selective neutralization of CXCL12, with chalcone 4-phosphate (C4P), inhibited AMD3100-stimulated mobilization of HPCs and leukocytes in naïve mice and MPCs in VEGF-A pretreated mice. In contrast it is shown here that the CXCR4 antagonist KRH3955 that binds to the extracellular loop of CXCR4 does not reverse the CXCL12 chemokine gradient. However, this drug efficiently mobilizes HPCs, a response that is not inhibited by C4P. In contrast, KRH3955 does not mobilize MPCs in VEGF-A pretreated mice. These data suggest that CXCR4 antagonists that bind to distinct regions of the receptor mobilize progenitor cells by distinct molecular mechanisms

show abstract

Section: Discussionmentioning

confidence: 79%

Section: Discussionmentioning

confidence: 99%

Two distinct CXCR4 antagonists mobilize progenitor cells in mice by different mechanisms

et al. 2017

Self Cite

View full text Add to dashboard Cite

show abstract

“…Although over-expression of vascular endothelial growth factor (VEGF) has been shown to impede improvements in biomechanical strength after ACL regeneration, blocking VEGF significantly reduced angiogenesis, graft maturation and biomechanical strength [56]. Despite a supportive role in delivering oxygen and nutrients, the perivascular cells have been demonstrated to play an important role in contributing to mesoderm tissue growth and repair but will result in pathological fibrosis if overstimulated [57][58][59][60]. These previous studies emphasized the requirement for proper dynamic vascularity during ACL regeneration.…”

Section: Discussionmentioning

confidence: 99%

Ectopic tissue engineered ligament with silk collagen scaffold for ACL regeneration: A preliminary study

Ran

et al. 2017

Acta Biomaterialia

View full text Add to dashboard Cite

a b s t r a c tAnterior cruciate ligament (ACL) reconstruction remains a formidable clinical challenge because of the lack of vascularization and adequate cell numbers in the joint cavity. In this study, we developed a novel strategy to mimic the early stage of repair in vivo, which recapitulated extra-articular inflammatory response to facilitate the early ingrowth of blood vessels and cells. A vascularized ectopic tissue engineered ligament (ETEL) with silk collagen scaffold was developed and then transferred to reconstruct the ACL in rabbits without interruption of perfusion. At 2 weeks after ACL reconstruction, more wellperfused cells and vessels were found in the regenerated ACL with ETEL, which decreased dramatically at the 4 and 12 week time points with collagen deposition and maturation. ACL treated with ETEL exhibited more mature ligament structure and enhanced ligament-bone healing post-reconstructive surgery at 4 and 12 weeks, as compared with the control group. In addition, the ETEL group was demonstrated to have higher modulus and stiffness than the control group significantly at 12 weeks post-reconstructive surgery. In conclusion, our results demonstrated that the ETEL can provide sufficient vascularity and cellularity during the early stages of healing, and subsequently promote ACL regeneration and ligament-bone healing, suggesting its clinic use as a promising therapeutic modality. Statement of SignificanceEarly inflammatory cell infiltration, tissue and vessels ingrowth were significantly higher in the extraarticular implanted scaffolds than theses in the joint cavity. By mimicking the early stages of wound repair, which provided extra-articular inflammatory stimulation to facilitate the early ingrowth of blood vessels and cells, a vascularized ectopic tissue engineered ligament (ETEL) with silk collagen scaffold was constructed by subcutaneous implantation for 2 weeks. The fully vascularized TE ligament was then transferred to rebuild ACL without blood perfusion interruption, and was demonstrated to exhibit improved ACL regeneration, bone tunnel healing and mechanical properties.

show abstract

“…Mesenchymal stem cells (MSCs) are multipotent cells in bone marrow and various other tissues, which are capable of differentiating into osteogenic cells, especially osteoblasts, as well as chondrogenic and adipogenic lineages by culturing in appropriate in vitro conditions (18). MSCs have been identified in adipose tissue, which are termed adipose tissue-derived MSCs (AT-MSCs) (19)(20)(21).…”

mentioning

confidence: 99%

Retraction：Polyphosphate-induced matrix metalloproteinase-13 is required for osteoblast-like cell differentiation in human adipose tissue derived mesenchymal stem cells

Ozeki

Mogi

Hase

et al. 2016

BST

View full text Add to dashboard Cite

Pericytes, mesenchymal stem cells and their contributions to tissue repair

Cited by 143 publications

References 153 publications

Two distinct CXCR4 antagonists mobilize progenitor cells in mice by different mechanisms

Two distinct CXCR4 antagonists mobilize progenitor cells in mice by different mechanisms

Ectopic tissue engineered ligament with silk collagen scaffold for ACL regeneration: A preliminary study

Retraction：Polyphosphate-induced matrix metalloproteinase-13 is required for osteoblast-like cell differentiation in human adipose tissue derived mesenchymal stem cells

Contact Info

Product

Resources

About